-

Sonoma Biotherapeutics Announces Poster Presentation at the 2025 European Alliance of Associations for Rheumatology (EULAR) Congress

SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing a poster presentation at the 2025 European Alliance of Associations for Rheumatology (EULAR) Congress, taking place in Barcelona on June 11-14, 2025.

Details of the presentations are as follows:

Poster Presentation Details:

  • Title: “REGULATE-RA: A Phase 1 Study of CAR-Treg Cells Targeting Citrullinated Proteins in Refractory Rheumatoid Arthritis: Interim Report of Patient Characteristics and Safety”
  • Presenting Author: Sarah K. Baxter, MD, PhD
  • Poster number: POS0034
  • Session: Clinical Poster Tours: Difficult to treat Rheumatoid Arthritis
  • Date/ Time: June 11, 2025; 16:12-16:18 CEST
  • Location: Poster Tour IV

About Sonoma Biotherapeutics
Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted and durable Treg cell therapies. Sonoma Biotherapeutics is based in South San Francisco and Seattle. For more information, visit sonomabio.com and follow on X, formerly Twitter, and LinkedIn.

Contacts

Investors:
ir@sonomabio.com

Media:
Stephanie Jacobson, Argot Partners
media@sonomabio.com

Industry:

Sonoma Biotherapeutics, Inc.

Release Versions
English

Contacts

Investors:
ir@sonomabio.com

Media:
Stephanie Jacobson, Argot Partners
media@sonomabio.com

More News From Sonoma Biotherapeutics, Inc.

Sonoma Biotherapeutics Announces Transition of Jeff Bluestone, PhD, to Advisor; Appoints Stephen Dilly, MBBS, PhD, as President and Chief Executive Officer

SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced that its Board of Directors has appointed Stephen Dilly, MBBS, PhD, former President and Chief Executive Officer (CEO) of Codexis, Inc., and current Chair of the Codexis Board, as the Company’s new President, CEO and member of the Board of Directors, effectiv...

Sonoma Biotherapeutics Announces Upcoming Poster Presentation at the 10th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)

SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing a poster presentation at the 10th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA), taking place in Nashville, TN from October 31 to November 2, 2025. Details of the presentation below: Title: “Regulate-HS: A Phase 1 Study CAR-Tregs Targeting Citr...

Sonoma Biotherapeutics Announces Positive Interim Safety and Efficacy Data from Phase 1 REGULATE-RA Study of SBT-77-7101 in Refractory Rheumatoid Arthritis

SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced interim safety and efficacy data from the Phase 1 Regulate-RA clinical trial. The results will be featured as a late-breaking oral presentation today at 8:00 a.m. CT at the 2025 American College of Rheumatology (ACR) Convergence, taking place in Chicago, IL....
Back to Newsroom